Cite
HARVARD Citation
Barron, M. et al. (2022). Can the 21-gene recurrence score (RS) assay spare some patients from unnecessary adjuvant chemotherapy in hormone–receptor-positive, HER2 negative early breast cancer with low burden axillary disease. European journal of surgical oncology. 48 (2), pp. e83-. [Online].